CCL18 and interstitial lung disease: Thus, our findings suggest that the evaluation of CCL18 at baseline could help stratifying the risk of IIMs patients with ILD leading to a close monitoring of patients at higher risk to develop PF-ILD by reassessing PFTs and HRCT to the optimization of patients’ management (e.g., adopting a more aggressive therapeutic strategy in earlier stages of IIMs-ILD).